[1]张文博 谢进生.经导管主动脉瓣中瓣植入术的并发症及其处理进展[J].心血管病学进展,2021,(1):1-4.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
 ZHANG Wenbo,XIE Jinsheng.Complications and Management of Valve-in-valve Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(1):1-4.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
点击复制

经导管主动脉瓣中瓣植入术的并发症及其处理进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年1期
页码:
1-4
栏目:
综述
出版日期:
2021-01-25

文章信息/Info

Title:
Complications and Management of Valve-in-valve Transcatheter Aortic Valve Replacement
文章编号:
202007003
作者:
张文博 谢进生
首都医科大学附属北京安贞医院,北京 100029)
Author(s):
ZHANG WenboXIE Jinsheng
(Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
关键词:
经导管主动脉瓣植入术瓣中瓣手术并发症处理
Keywords:
Transcatheter aortic valve replacementValve-in-valveComplication management
DOI:
10.16806/j.cnki.issn.1004-3934.2021.01.000
摘要:
经导管主动脉瓣中瓣植入术是生物瓣毁损后最理想的二次和多次干预手段之一,尤其适合于高危或不耐受手术患者。随着此类术式在国内外临床应用和报道的不断增加,新技术同样带来了新问题,如冠状动脉阻塞和术后跨瓣压差增高等,因此对其发生机制及处理最新进展加以综述就变得十分必要。
Abstract:
Valve-in-valve transcatheter aortic valve replacement is one of the most ideal secondary and multiple interventions after bioprosthetic prostheses structural valve deterioration, especially for patients with high risk or intolerance of surgery. With the increasing number of such cases and reports at home and abroad, there are also brought new problems with new technology,such as the high risk of coronary obstruction ,significant postoperative residual gradients, etc. Therefore, it’s necessary to review the latest progress in the pathogenesis and treatment of these diseases

参考文献/References:

[1] Barbanti M,Costa G,Zappulla P,et al. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement[J]. J Am Heart Assoc,2018,7(15):e008440.

[2] Nishimura RA,Otto CM,Bonow RO,et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation,2017,135(25):e1159-e1195.

[3] Ejiofor JI,Yammine M,Harloff MT,et al. Reoperative surgical aortic valve replacement versus transcatheter valve-in-valve replacement for degenerated bioprosthetic aortic valves[J]. Ann Thorac Surg,2016,102(5):1452-1458.

[4] Wenaweser P,Buellesfeld L,Gerckens U,et al. Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis:the first valve in valve procedure using the corevalve revalving system[J]. Catheter Cardiovasc Interv,2007,70(5):760-764.

[5] Edelman JJ,Khan JM,Rogers T,et al. Valve-in-valve TAVR:state-of-the-art review[J]. Innovations (Phila),2019,14(4):299-310.

[6] Tuzcu EM,Kapadia SR,Vemulapalli S,et al. Transcatheter aortic valve replacement of failed surgically implanted bioprostheses[J]. J Am Coll Cardiol,2018,72(4):370-382.

[7] Vemulapalli S,Holmes DR,Dai D,et al. Valve hemodynamic deterioration and cardiovascular outcomes in TAVR:a report from the STS/ACC TVT Registry[J]. Am Heart J,2018,195:1-13.

[8] Tam DY,Vo TX,Wijeysundera HC,et al. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve:a systematic review and meta-analysis[J]. Catheter Cardiovasc Interv,2018,92(7):1404–1411.

[9] Wai Sang SL, DeBruine N, Beute T,et al. Midterm outcomes for valve-in-valve TAVR in the failed freestyle bioprosthesis[J]. Ann Thorac Surg,2020,May 19.S0003-4975(20)30729-3.DOI: 10.1016/j.athoracsur.2020.03.116.?Online ahead of print.

[10] Mahmoud AN,Gad MM,Elgendy IY,et al. Outcomes of valve-in-valve transcatheter aortic valve replacement in patients with failed bioprosthetic aortic valves:systematic review and meta-analysis of observational evidence[J]. EuroIntervention,2020,May 19.EIJ-D-19-00928.DOI:10.4244/EIJ-D-19-00928.?Online ahead of print.

[11] Spaziano M,Mylotte D,Thériault-Lauzier P,et al. Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses:a multicentre propensity score analysis[J]. EuroIntervention,2017,13(10):1149-1156.

[12] Ribeiro HB,Rodés-Cabau J,Blanke P,et al. Incidence,predictors,and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves:insights from the VIVID Registry[J]. Eur Heart J,2018,39(8):687-695.

[13] Dvir D,Webb JG,Bleiziffer S,et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves[J]. JAMA,2014,312(2):162.

[14] Pibarot P,Simonato M,Barbanti M,et al. Impact of pre-existing prosthesis-patient mismatch on survival following aortic valve-in-valve procedures[J]. JACC Cardiovasc Interv,2018,11(2):133-141.

[15] Jose J,Sulimov DS,El-Mawardy M,et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic?valve replacement:incidence, characteristics,and treatment outcomes[J]. JACC Cardiovasc Interv,2017,10(7):686-697.

[16] Vahidkhah K,Javani S,Abbasi M,et al. Blood stasis on transcatheter valve leaflets and implications for valve-in-valve leaflet thrombosis[J]. Ann Thorac Surg,2017,104(3):751-759.

[17] Abdel-Wahab M,Simonato M,Latib A,et al. Clinical valve thrombosis after transcatheter aortic valve-in-valve implantation[J]. Circ Cardiovasc Interv,2018,11(11):e006730.

[18] Bernardi FLM,Dvir D,Rodes-Cabau J,et al. Valve-in-valve challenges:how to avoid coronary obstruction[J]. Front Cardiovasc Med,2019,6:120.

[19] Ribeiro HB,Nombela-Franco L,Allende R,et al. Coronary obstruction following transcatheter aortic valve implantation for degenerative bioprosthetic surgical valves:a systematic literature review[J]. Rev Bras Cardiol Invasiva Engl Ed,2013,21(4):311-318.

[20] Ribeiro HB,Webb JG,Makkar RR,et al. Predictive factors,management,and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation:insights from a large multicenter registry[J]. J Am Coll Cardiol,2013,62(17):1552-1562.

[21] Maggio S,Gambaro A,Scarsini R,et al. Preventive left main and right coronary artery stenting to avoid coronary ostia occlusion in high-risk stentless valve-in-valve transcatheter aortic valve implantation[J]. Interact Cardiovasc Thorac Surg,2017,25(1):147-149.

[22]Edelman JJ,Khan JM,Rogers T,et al. Valve-in-valve TAVR:state-of-the-art review[J]. Innovations,2019,14(4):299-310.

[23] Khan JM,Dvir D,Greenbaum AB,et al. Transcatheter laceration of aortic leaflets to prevent coronary?obstruction?during transcatheter aortic?valve replacement:concept to first-in-human[J]. JACC Cardiovasc Interv,2018,11(7):677-689.

[24] Jabbour RJ,Tanaka A,Finkelstein A,et al. Delayed coronary obstruction after transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2018,71(14):1513–1524.

[25] Yaakobovich H,Plitman Mayo R,Zaretsky U,et al. Numerical models of valve-in-valve implantation:effect of intentional leaflet laceration on the anchorage[J]. Biomech Model Mechanobiol,2020,19(2):415-426.

[26] Herrmann HC,Daneshvar SA,Fonarow GC,et al. Prosthesis–patient mismatch in?patients?undergoing transcatheter?aortic?valve replacement:from the STS/ACC TVT Registry[J]. J Am Coll Cardiol,2018,72(22):2701-2711.

[27] Deeb GM,Reardon MJ,Chetcuti S,et al. 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2016,67(22):2565-2574.

[28] Flameng W,Herregods MC,Vercalsteren M,et al. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves[J]. Circulation,2010,121(19):2123-2129.

[29] Azadani AN,Reardon M,Simonato M,et al. Effect of transcatheter aortic valve size and position on valve-in-valve hemodynamics:an in vitro study[J]. J Thorac Cardiovasc Surg,2017,153(6):1303-1315.e1.

[30] Zenses AS,Evin MA,Stanová V,et al. Effect of size and position of self-expanding transcatheter valve on haemodynamics following valve-in-valve procedure in small surgical bioprostheses:an in vitro study[J]. EuroIntervention,2018,14(3):e282-e289.

[31] Sathananthan J,Fraser R,Kütting M,et al. Impact of implant depth on hydrodynamic function of the ALLEGRA bioprosthesis in valve-in-valve interventions[J]. EuroIntervention,2020,15(15):e1335-e1342.

[32] Grubitzsch H,Galloni M,Falk V. Wrinkles,folds and calcifications:reduced durability after transcatheter aortic valve-in-valve replacement[J]. J Thorac Cardiovasc Surg,2017,153(2):266-268.

[33] Allen KB,Chhatriwalla AK,Cohen DJ,et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation[J]. Ann Thorac Surg,2017,104(5):1501-1508.

[34] Chhatriwalla Adnan K,Allen Keith B,Saxon John T,et al. Bioprosthetic valve fracture improves the hemodynamic results of valve-in-valve transcatheter aortic valve replacement[J]. Circ Cardiovasc Interv,2017,10(7):e005216.

[35] Feindel CM. Aortic root enlargement in the adult[J]. Oper Tech Thorac Cardiovasc Surg,2006,11(1):2-15.

[36] Chakravarty T,S?ndergaard L,Friedman J,et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves:an observational study[J]. Lancet,2017,389(10087):2383-2392.

相似文献/References:

[1]王慧,饶莉.经导管主动脉瓣植入术的影像学研究进展[J].心血管病学进展,2015,(5):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
 WANG Hui,RAO Li.Advances in Study of Imaging of Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(1):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
[2]蒲华霞 彭礼清.多层螺旋CT在经导管主动脉瓣植入术前评估中的研究进展[J].心血管病学进展,2019,(9):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
 PU HuaxiaPeng Liqing.Preoperative Evaluation of Transcatheter Aortic Valve Implantation with Multi-detector Computed Tomography[J].Advances in Cardiovascular Diseases,2019,(1):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
[3]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
 DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[4]何佳玲 陈应忠 刘浩然 叶滔 谢轲 徐俊波 刘汉雄 蔡琳.预防性静脉-动脉体外膜肺氧合支持下的经导管主动脉瓣植入术[J].心血管病学进展,2022,(2):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
 HE JialingCHEN YingzhongLIU HaoranYE TaoXIE KeXU Junbo,LIU HanxiongCAI Lin.Prophylactic Venous-Arterial Extracorporeal Membrane Oxygenation Supported Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(1):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
[5]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
 WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
[6]周浩 兰富霞 徐英.经导管主动脉瓣植入术后发生脑血管事件的研究进展[J].心血管病学进展,2023,(11):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]
 ZHOU Hao,LAN Fuxia,XU Ying.Cerebrovascular Events After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2023,(1):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]

更新日期/Last Update: 2021-03-17